Literature DB >> 15870511

Prognostic factors in papillary thyroid cancer: an evaluation of 601 consecutive patients.

Päivi Siironen1, Johanna Louhimo, Stig Nordling, Ari Ristimäki, Hanna Mäenpää, Reijo Haapiainen, Caj Haglund.   

Abstract

BACKGROUND: Although papillary thyroid cancer (PTC) is among the most curable cancer types, it can be a distressing disease for those patients suffering from frequent recurrences or even distant metastases leading to death. Age over 45 years is the most important indicator of poor prognosis. Our aim was to evaluate markers which might predict the outcome of an individual patient better than does TNM classification alone.
MATERIALS AND METHODS: Of 601 consecutive patients who underwent surgery for PTC, retrospectively we selected 36 patient pairs in which one recovered completely after primary surgery, and the other suffered from aggressive disease. Formalin-fixed, paraffin-embedded tumor samples from these 72 patients were analyzed by immunohistochemistry for COX-2, MMP-2, VEGF-C, Bcl-2, Ki-67, and p21 expression. RESULTS AND
CONCLUSIONS: None of the markers we studied showed a superiority over TNM classification in selecting patients likely to progress to aggressive disease. However, the expression of COX-2 and VEGF-C seemed to be increased in patients over 45, which could explain the more aggressive behavior of these tumors. Moreover, we found that age over 45, tumor size over 4 cm, extrathyroidal extension of tumor, nodal metastases, distant metastases, and stage IV had an unfavorable effect on survival. Copyright (c) 2005 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15870511     DOI: 10.1159/000085586

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  25 in total

1.  Prognostic factors of papillary thyroid carcinoma vary according to sex and patient age.

Authors:  Yasuhiro Ito; Takumi Kudo; Yuuki Takamura; Kaoru Kobayashi; Akihiro Miya; Akira Miyauchi
Journal:  World J Surg       Date:  2011-12       Impact factor: 3.352

2.  Prognosis of patients with papillary thyroid carcinoma showing postoperative recurrence to the central neck.

Authors:  Yasuhiro Ito; Takuya Higashiyama; Yuuki Takamura; Kaoru Kobayashi; Akihiro Miya; Akira Miyauchi
Journal:  World J Surg       Date:  2011-04       Impact factor: 3.352

3.  2-Deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and positron emission tomography/computed tomography diagnosis of patients with recurrent papillary thyroid cancer.

Authors:  Andrei Iagaru; Rinat Masamed; Peter A Singer; Peter S Conti
Journal:  Mol Imaging Biol       Date:  2006 Sep-Oct       Impact factor: 3.488

4.  c-Met inhibitor synergizes with tumor necrosis factor-related apoptosis-induced ligand to induce papillary thyroid carcinoma cell death.

Authors:  Rong Bu; Shahab Uddin; Maqbool Ahmed; Azhar R Hussain; Saif Alsobhi; Tarek Amin; Abdurahman Al-Nuaim; Fouad Al-Dayel; Jehad Abubaker; Prashant Bavi; Khawla S Al-Kuraya
Journal:  Mol Med       Date:  2012-03-27       Impact factor: 6.354

5.  Genomic Profiling of Thyroid Cancer Reveals a Role for Thyroglobulin in Metastasis.

Authors:  Abdul K Siraj; Tariq Masoodi; Rong Bu; Shaham Beg; Saif S Al-Sobhi; Fouad Al-Dayel; Mohammed Al-Dawish; Fowzan S Alkuraya; Khawla S Al-Kuraya
Journal:  Am J Hum Genet       Date:  2016-05-26       Impact factor: 11.025

6.  Overexpression of epidermal growth factor receptor and its downstream effector, focal adhesion kinase, correlates with papillary thyroid carcinoma progression.

Authors:  Sonja Šelemetjev; Aleksandar Bartolome; Tijana Išić Denčić; Ilona Đorić; Ivan Paunović; Svetislav Tatić; Dubravka Cvejić
Journal:  Int J Exp Pathol       Date:  2018-04-17       Impact factor: 1.925

7.  Prognostic significance of ki-67 labeling index in papillary thyroid carcinoma.

Authors:  Yasuhiro Ito; Akira Miyauchi; Kennichi Kakudo; Mitsuyoshi Hirokawa; Kaoru Kobayashi; Akihiro Miya
Journal:  World J Surg       Date:  2010-12       Impact factor: 3.352

8.  Differential effects of cetuximab and AEE 788 on epidermal growth factor receptor (EGF-R) and vascular endothelial growth factor receptor (VEGF-R) in thyroid cancer cell lines.

Authors:  S Hoffmann; A Burchert; A Wunderlich; Y Wang; S Lingelbach; L C Hofbauer; M Rothmund; A Zielke
Journal:  Endocrine       Date:  2007-04       Impact factor: 3.633

9.  Should patients with remnants from thyroid microcarcinoma really not be treated with iodine-131 ablation?

Authors:  Rosj Gallicchio; Sabrina Giacomobono; Daniela Capacchione; Anna Nardelli; Francesco Barbato; Antonio Nappi; Teresa Pellegrino; Giovanni Storto
Journal:  Endocrine       Date:  2013-03-28       Impact factor: 3.633

10.  The comparison of serum vascular endothelial growth factor levels between patients with metastatic and non-metastatic thyroid cancer, and patients with nontoxic multinodular goiter.

Authors:  Joanna Klubo-Gwiezdzinska; Roman Junik; Ewa Kopczynska; Olga Juraniec; Hanna Kardymowicz
Journal:  Eur J Endocrinol       Date:  2007-10       Impact factor: 6.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.